ODTXOdyssey Therapeutics, Inc.
The schedule
- Tue20Oct
Potential secondary equity offering or at-the-market (ATM) program to extend Odyssey Therapeutics’ cash runway as the company funds ongoing R&D. Structure, size, and discount relative to the trading price will drive the share-price reaction.
- Sun22Nov
Management’s year-end 2026 update on Odyssey Therapeutics’ oncology pipeline, including any first-in-human initiations, dose-escalation progress, or key preclinical data that frame the commercial potential of its next-generation therapeutics.
- Sat13Feb
- Sat15May
Q4 2026 earnings release with full-year cash burn, updated 2027 R&D budget, and runway commentary for Odyssey Therapeutics’ clinical programs.
- Sat14Aug
Past
- Sat15Aug
Q2 2026 earnings and cash runway commentary around Odyssey Therapeutics’ R&D burn and liquidity position. With no meaningful revenue and negative free cash flow, the focus will be how long the current $35.7M cash balance funds the pipeline and whether management signals the need for additional capital.